GNPX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Genprex Inc (GNPX) is not a good buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock exhibits bearish technical indicators, weak financial performance, and lacks strong positive catalysts to justify an immediate investment. Additionally, there are no significant trading signals or insider/congressional activity to support a buy decision.
The technical indicators for GNPX are bearish. The MACD is negatively expanding, the RSI is neutral at 34.619, and the moving averages (SMA_200 > SMA_20 > SMA_5) suggest a downward trend. The stock is trading below key pivot levels, with a support level at 1.971 and resistance at 2.334. Overall, the technical setup does not favor a buy at this time.
The EGFR-NSCLC market is projected to grow significantly, reaching $6 billion by 2024, with increasing demand for targeted therapies. This provides a potential long-term opportunity for companies in this space.
The competition in the EGFR-NSCLC market is intensifying with new drugs and therapies entering clinical trials. Additionally, the company's financial performance is weak, with declining net income and EPS, and no revenue growth.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income drop of -11.97% YoY to -$3,799,240, and a significant EPS decline of -91.89% YoY to -5. Gross margin remains at 0%. These metrics indicate poor financial health and no signs of improvement.
No analyst rating or price target data is available for GNPX. This lack of coverage may indicate limited interest or confidence from Wall Street analysts.
